Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Theravance Biopharma ( (TBPH) ) has provided an announcement.
On March 3, 2026, Theravance Biopharma reported that its Phase 3 CYPRESS trial of ampreloxetine in patients with symptomatic neurogenic orthostatic hypotension due to multiple system atrophy failed to meet its primary endpoint, leading the company to wind down the program and complete further data analyses only to assess any residual value. In parallel, the board’s Strategic Review Committee moved to accelerate an ongoing review of strategic alternatives, including a potential sale, while management launched an organizational restructuring that will eliminate the R&D function, cut roughly half of the workforce, and reduce operating expenses by about 60%, positioning Theravance around its cash-generating YUPELRI franchise, substantial cash balance and TRELEGY milestone potential to deliver $60–70 million in annualized cash flow from the third quarter of 2026.
The most recent analyst rating on (TBPH) stock is a Buy with a $27.00 price target. To see the full list of analyst forecasts on Theravance Biopharma stock, see the TBPH Stock Forecast page.
Spark’s Take on TBPH Stock
According to Spark, TipRanks’ AI Analyst, TBPH is a Neutral.
The score is driven primarily by a strong, positive earnings-call outlook (record YUPELRI performance, breakeven execution, sizable cash with no debt, and near-term milestone catalysts) and supportive technical momentum (price above key moving averages with positive MACD). Offsetting these positives are only mid-range underlying financial performance due to negative EBIT/EBITDA margins and a merely moderate valuation profile with a high P/E and no dividend yield.
To see Spark’s full report on TBPH stock, click here.
More about Theravance Biopharma
Theravance Biopharma, Inc. is a Dublin-based biopharmaceutical company focused on respiratory medicine, with its key commercial asset being YUPELRI, a once-daily nebulized LAMA bronchodilator for the maintenance treatment of chronic obstructive pulmonary disease in the U.S. The company holds a 35% economic interest in YUPELRI under a profit-and-loss sharing arrangement with Viatris and also derives value from TRELEGY-related milestones and Irish tax attributes.
Average Trading Volume: 459,633
Technical Sentiment Signal: Buy
Current Market Cap: $960.2M
For an in-depth examination of TBPH stock, go to TipRanks’ Overview page.